Brazil to help test Oxford’s Covid-19 vaccine
Team Udayavani, Jun 5, 2020, 3:02 PM IST
Brazil will soon start testing an experimental vaccine against the novel coronavirus being developed by researchers at the University of Oxford, supported by AstraZeneca
The vaccine will be tested in Brazil on 2,000 volunteers, who will be recruited starting this week.
Soraya Smaili, Brazilian university’s president, said, “Volunteers must be health professionals between 18 and 55 years old and be at high risk of infection, for example, cleaning and support staff in units treating Covid-19 patients”
Andrew Pollard, chief investigator of the Oxford Vaccine Trial at Oxford, said: “We are delighted to be working with the talented team of investigators in Brazil on the Covid-19 vaccine trial, as researchers and scientists around the world collaborate on clinical development work with unprecedented urgency to combat the global threat to human health that is coronavirus.”
The Oxford University vaccine, supported by AstraZeneca, is among the first Covid-19 vaccines to move into Phase II, or mid-stage, trials, along with one from the U.S. biotech company Moderna Inc
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
‘Faster walkers’ had significantly lower risk of diabetes, hypertension: Study
World Meditation Day 2024: Celebrating inner peace and well-being
Virus causing gut infections could play role in development of Alzheimer’s: Study
Air pollution linked to more hospitalisations for all causes, mental illness too, study finds
Plant-based meat alternatives linked to increased risk of depression in vegetarians, study finds
MUST WATCH
Latest Additions
ISRO to study how crops grow in space on PSLV-C60 mission
Vandalism at Allu Arjun’s residence in Hyderabad
PM Modi to attend Christmas celebrations hosted by Catholic Bishops’ Conference of India
Malpe: Carol singing brings Christmas cheer to homes
UP: Ancient stepwell unearthed in Sambhal district’s Chandausi
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.